Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

Role of the endocannabinoid system in metabolic control

(2009) Jun Wang et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Orlistat-Associated Adverse Effects and Drug Interactions

(2009) Theodosios D Filippatos et al.   DRUG SAFETY

Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results

(2009) Luis M Ruilope et al.   JOURNAL OF HYPERTENSION

Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies

(2008) Bernard Le Foll et al.   ADDICTION BIOLOGY

The Discovery of Taranabant, a Selective Cannabinoid‐1 Receptor Inverse Agonist for the Treatment of Obesity

(2008) William K. Hagmann   ARCHIV DER PHARMAZIE

The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake

(2008) Carol Addy et al.   Cell Metabolism

Ligand-Binding Architecture of Human CB2 Cannabinoid Receptor: Evidence for Receptor Subtype-Specific Binding Motif and Modeling GPCR Activation

(2008) Ying Pei et al.   CHEMISTRY & BIOLOGY

Rimonabant: New data and emerging experience

(2008) Suzanne M. Wright et al.   Current Atherosclerosis Reports

Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment

(2008) Jennifer M. Perkins et al.   Current Diabetes Reports

Endocannabinoid system in food intake and metabolic regulation

(2008) David Jesudason et al.   CURRENT OPINION IN LIPIDOLOGY

CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications

(2008) Nadine Jagerovic et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Overview of the Chemical Families of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitors

(2008) Severine Vandevoorde   CURRENT TOPICS IN MEDICINAL CHEMISTRY

The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in Endocannabinoids

(2008) T. M. D'Eon et al.   DIABETES

Neurophysiological Pathways to Obesity: Below Awareness and Beyond Individual Control

(2008) D. A. Cohen   DIABETES

Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats

(2008) R. Nogueiras et al.   DIABETES

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES CARE

Treatment Modalities of Obesity: What fits whom?

(2008) V. Hainer et al.   DIABETES CARE

Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program

(2008) L. Van Gaal et al.   DIABETES CARE

The endocannabinoid system in obesity and type 2 diabetes

(2008) V. Di Marzo   DIABETOLOGIA

The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS

(2008) U. Kintscher   EUROPEAN HEART JOURNAL

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

(2008) Luc F. Van Gaal et al.   EUROPEAN HEART JOURNAL

Surgical treatment of obesity

(2008) Mariëlle J F Bult et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor

(2008) Richard Z. Chen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sibutramine: current status as an anti-obesity drug and its future perspectives

(2008) Bikash Sharma et al.   EXPERT OPINION ON PHARMACOTHERAPY

Is rimonabant efficacious and safe in the treatment of obesity?

(2008) Sheila A Doggrell   EXPERT OPINION ON PHARMACOTHERAPY

Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations

(2008) Michael Benzinou et al.   HUMAN MOLECULAR GENETICS

Modulation of the Endocannabinoid System in Cardiovascular Disease

(2008) Pál Pacher et al.   HYPERTENSION

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Hope and Fear of Rimonabant

(2008) John S. Rumsfeld   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors

(2008) Meritxell Canals et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Endocannabinoids and the Control of Energy Homeostasis

(2008) George Kunos et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Health

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence

(2008) Michael Soyka et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The epidemiology of obesity: the size of the problem

(2008) W. P. T. James   JOURNAL OF INTERNAL MEDICINE

Endocannabinoids: Some Like it Fat (and Sweet Too)

(2008) I. Matias et al.   JOURNAL OF NEUROENDOCRINOLOGY

CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant

(2008) A. J. Scheen   JOURNAL OF NEUROENDOCRINOLOGY

The Endocannabinoid System and the Control of Glucose Homeostasis

(2008) R. Nogueiras et al.   JOURNAL OF NEUROENDOCRINOLOGY

Dysregulation of the Endocannabinoid System in Obesity

(2008) S. Engeli   JOURNAL OF NEUROENDOCRINOLOGY

Cannabinoid Receptors: Where They are and What They do

(2008) K. Mackie   JOURNAL OF NEUROENDOCRINOLOGY

Endogenous Cannabinoids: Structure and Metabolism

(2008) T. Bisogno   JOURNAL OF NEUROENDOCRINOLOGY

The Endocannabinoid System and Energy Metabolism

(2008) L. Bellocchio et al.   JOURNAL OF NEUROENDOCRINOLOGY

Neurobiological mechanisms of cannabinoid addiction

(2008) L. Fattore et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Signaling via CNS cannabinoid receptors

(2008) Ken Mackie   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets

(2008) Isabel Matias et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

(2008) Jonathan Z Long et al.   Nature Chemical Biology

Decoding endocannabinoid signaling

(2008) Lawrence J Marnett   Nature Chemical Biology

End of the line for cannabinoid receptor 1 as an anti-obesity target?

(2008) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

Targeting the endocannabinoid system: to enhance or reduce?

(2008) Vincenzo Di Marzo   NATURE REVIEWS DRUG DISCOVERY

Are Non-prescription Medications Needed for Weight Control?

(2008) George A. Bray   Obesity

Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet

(2008) Katarzyna M. Starowicz et al.   Obesity

A critical review of the cannabinoid receptor as a drug target for obesity management

(2008) F. Akbas et al.   Obesity Reviews

Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats

(2008) T JARBE et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113

(2008) K.S. Sink et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?

(2008) George Kunos et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Co-occurring Mental Illness and Health Care Utilization and Expenditures in Adults with Obesity and Chronic Physical Illness

(2008) Chan Shen et al.   Disease management : DM

Biological specificity of visceral adipose tissue and therapeutic intervention

(2008) Sebastio Perrini et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications

(2008) M. Viveros et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

Bioisosteric replacement of dihydropyrazole of 4S-(−)-3-(4-chlorophenyl)-N-methyl-N′-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole

(2007) Brijesh Kumar Srivastava et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Novel cannabinoid receptors

(2007) A J Brown   BRITISH JOURNAL OF PHARMACOLOGY

Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor

(2007) R A Ross   BRITISH JOURNAL OF PHARMACOLOGY

The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action

(2007) C J Fowler   BRITISH JOURNAL OF PHARMACOLOGY

Sibutramine-associated adverse effects: a practical guide for its safe use

(2007) M. Florentin et al.   Obesity Reviews

Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome

(2007) V. Kiran Vemuri et al.   PHYSIOLOGY & BEHAVIOR

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties

(2007) Jack Bergman et al.   PHYSIOLOGY & BEHAVIOR

In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?

(2006) B B Yao et al.   BRITISH JOURNAL OF PHARMACOLOGY